×

Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023: Transparency Market Research

Albany, NY, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies. The drugs are based on simple chemistries to highly advanced complex protein. The market is witnessing strong growth due to high awareness among the population through government initiatives. Moreover, the drugs for NSCLC are given swift approvals by regulatory bodies and grants for research. This has led to new generation of drugs being introduced in the NSCLC market.

Browse Market Research Report on Non-Small Cell Lung Cancer Therapeutics Market: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014.

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies

Browse Regional Analysis: http://www.europlat.org/global-non-small-cell-lung-cancer-nsclc-therapeutics-market-expected-to-reach-us-15-1-bn-in-2023-transparency-market-research.htm

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, BoehringerIngelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.

Browse Press Release of Non-Small Cell Lung Cancer Therapeutics Market:http://www.transparencymarketresearch.com/pressrelease/non-small-cell-lung-cancer-market.htm

Other Reports by Transparency Market Research:

LATAM Cord Blood Banking Services Market: http://www.transparencymarketresearch.com/latam-cord-blood-banking-services-market.html

Menopausal Hot Flashes Market:http://www.transparencymarketresearch.com/menopausal-hot-flashes.html

High Potency Active Pharmaceutical Ingredient (HPAPI) Market:http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

About Us:

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr.Sudip.S 90 State Street, Suite 700 Albany, NY 12207 United States. Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Blog: http://www.tmrblog.com/

Source:Transparency Market Research